When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CALA - Calithera Bio completes enrollment in mid-stage study of CB-839 in kidney cancer
Calithera Biosciences Inc.
Calithera Biosciences (NASDAQ:CALA) has completed enrollment in its Phase 2 ENTRATA study evaluating the combination of telaglenastat (CB-839) and Novartis' Afinitor (everolimus) in patients with advanced renal cell carcinoma (RCC).